Vir Biotechnology
@Vir_Biotech
Followers
3K
Following
159
Media
381
Statuses
645
We leverage the immense potential of the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer.
San Francisco, CA
Joined October 2017
Our CEO, Marianne De Backer, will open the @demy_sara #GlobalBiotechCEOSummit with the Purposeful CEO Series. She’ll share how strategic leadership and a clear mission propelled our expertise in powering the immune system, bringing us to the forefront of masked #TCE technology.
0
1
2
Healthcare providers are a key resource for people with #hepatitisdelta, yet most of the @Hep_Alliance survey respondents did not feel sufficiently informed about testing and treatment. This spotlight's a clear need to strengthen awareness of the disease.
2
0
2
As a panelist for the Student Program session at @IAmBioTech #BIO2025, Jeffrey Herrera, Assoc. Director of Human Resources at #VirBiotechnology, spoke about his own career journey in the biotech industry and how the work can make a lasting difference for patients.
0
0
2
Join a fireside chat with our CEO Marianne D. De Backer, MSc, PhD, MBA, at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 10, at 1 p.m. PT/4 p.m. ET. Watch the webcast live here ➡️ #HepatitisD #Oncology #Immunotherapy
0
0
2
The shared commitment at #ASCO25 to drive better outcomes for people with cancer – moved us. We know there are still many unmet needs of people affected by hard-to-treat solid tumors. #PatientsAreWaiting #Oncology #Immunotherapy
0
0
3
See you at #ASCO25! We look forward to connecting with you about the latest innovations in oncology. We are advancing multiple dual-masked TCEs to develop transformative treatments for people with hard-to-treat solid tumors. Learn more ➡️ #Immunotherapy
0
0
6
As we wrap-up #HepatitisAwarenessMonth, we continue our efforts in increasing awareness of #HepatitisDelta. In this first episode of Let's Ask!, our CMO Mark Eisner, shares key insights about the uniqueness of delta and the need for transformational treatment options.
0
0
4
Join a virtual fireside chat with our CEO Marianne D. De Backer, MSc, PhD, MBA, and Executive Vice President, Therapeutic Head of Oncology, Mika Kakefuda Derynck, M.D., at the TD Cowen 6th Annual Oncology Innovation Summit on May 27. Take part here ➡️
0
0
0
We feel grateful to engage with @Hep_Alliance about ways to address clear gaps in awareness, testing and treatments, found in the Hepatitis Delta Global Landscape Survey results. Read the full report here ➡️ #WHA #HepatitisDelta
1
0
1
Join a fireside chat with our Chief Executive Officer Marianne D. De Backer, MSc, PhD, MBA, at the Bank of America Securities 2025 Healthcare Conference at 1:40 p.m. PT/4:40 p.m. ET. Watch the webcast live here ➡️
0
0
0
We were thrilled to participate in #SwissBiotechDay alongside more than 3,000 attendees from 49 countries. We connected with like-minded innovators and now look forward to building on the great momentum from the conference. #PatientsAreWaiting
0
0
1
🌟 We feel honored to brainstorm with @EuropeLiver on our #hepatitisdelta investigational Phase 3 ECLIPSE study at EASL. Together, we’re finding ways to connect patients to our pivotal study to create a better future for people with hepatitis. Learn more:
0
6
8
📢 #VirBiotechnology News: Today our Chief Executive Officer Marianne D. De Backer, MSc, PhD, MBA, shared our Q1 2025 business and financial results. Listen to the call ➡️ Learn more about our latest achievements ➡️ #Earnings
0
0
0
📣 Gaps in knowledge and awareness of #hepatitis delta, even among community-based organizations, policymakers and healthcare providers – are key barriers to testing and treatment. Full results of the #WHA Hepatitis #Delta Global Landscape Survey here ➡️
0
0
2
👉 #VirBiotechnology will provide a corporate update and report Q1 financial results on Wed., May 7, at 1:30 p.m. PT/4:30 p.m. ET. Join us for our investor conference call. #Earnings
0
0
0
🧬 The #SwissBiotechDay is a prime event for the life sciences in Switzerland! Join #VirBiotechnology to learn more about how we are powering the #immune system to transform lives. Check all the details here ➡️
0
0
1
#VirBiotechnology will be at #EASLCongress 2025 to share the latest updates of our ongoing work in #hepatitisDelta and #hepatitisB. Find out more here ➡️
0
0
0
💡We are shining a light on some of our incredible leaders who drive scientific innovation, inspire teams and steer the future of #VirBiotechnology. We’re proud and grateful to be #MovingForwardTogether with them! Learn about our broader leadership team ➡️
0
0
2
📣Check out #VirBiotechnology on the iconic NASDAQ MarketSite Tower in the heart of Times Square shining a spotlight on the initiation of our Phase 3 ECLIPSE Registrational Program in chronic hepatitis delta! Read more here ➡️
1
0
4
🚀Phase 3 ECLIPSE registrational program in chronic #hepatitis #delta initiated. This is an important step forward on our path to delivering a highly effective treatment for people living with chronic hepatitis delta. Read more here➡️
0
1
3